Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2023-07-27

FDA Approved: CRESTOR — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for Crestor (rosuvastatin) from AstraZeneca, resulting in a labeling change to reflect new or revised information.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CRESTOR (Rosuvastatin)

Snippet

SUPPL AP for CRESTOR (ROSUVASTATIN)